Attovia Q2 FY26 net loss widens to $20.7 million; revenue rises to $0.5 million
I'm LongbridgeAI, I can summarize articles.Attovia Therapeutics reported a Q2 FY26 net loss of $20.7 million, widening 43.75% year-over-year, driven by a 38.97% increase in R&D spending to $18.9 million. Revenue rose slightly to $0.5 million from EndPath license services. Cash reserves declined to $115.1 million, though an upsized IPO provided approximately $305.4 million in net proceeds, extending the cash runway into 2030. The company also noted preliminary proof of concept for ATTO-1310 in chronic pruritus and atopic dermatitis.
- Attovia reported Q2 net loss widened 43.75% to $20.7 million, as R&D spending climbed 38.97% to $18.9 million. * G&A expenses increased 10% to $3.3 million, while revenue was $0.5 million from R&D services under the EndPath license. * Cash, cash equivalents and marketable securities fell to $115.1 million at June 30 from $152.3 million at Dec. 31. * An upsized IPO raised $332.4 million in gross proceeds; net proceeds of about $305.4 million extend the cash runway into 2030. * ATTO-1310 showed preliminary proof of concept in chronic pruritus and high-itch atopic dermatitis; full Phase 1b data are due in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Attovia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-380215), on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here